Defining platinum- and PARP-inhibitor-responsive molecular phenotypes of pancreatic cancer

The overall aim of Dr Biankin's research is to advance innovative approaches in cancer genomics for therapeutic development, with the aim of defining, understanding, testing and implementing personalised therapeutic strategies for pancreatic cancer. This research will focus on identifying patients who will respond to platinum-based therapies (which are emerging as the standard of care) and to PARP inhibitors that target similar mechanisms, so that only those who are likely to benefit receive these drugs. This also allows those who are unlikely to respond to avoid the toxicity of ineffective therapies and to receive treatments that are more likely to benefit them as individuals.